ACLS Pharmacology Lecture PDF Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Preferred routes of administration for ACLS medications (2)

A

-IV or IO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In cardiac arrest (Vfib and pulseless v tach) persists after at least 1 attempt of defib and 2 min of CPR, what should be administered?

A

Epi 1mg IV q3-5 min while CPR is performed continuously

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What may be administered in cardiac arrest (VF or pulseless VT) unresponsive to defibrillation, CPR, and epinephrine?

A

Amiodarone, 300mg IV, 150mg IV repeat dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When is magnesium sulfate (2g IV) used in cardiac arrest?

A

Polymorphic ventricuar tachycardia with torsades de pointes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Asystole/PEA are nonshockable rhythms that after initiating CPR for 2 min can give this drug

A

1mg epi every 3-5min IV/IO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

1st line treatment for nonstable bradycardia (BPM <50)

A

atropine .5mg bolus repeat every 3-5 min max 3 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

2nd line treatment for nonstable bradycardia (BPM <50)

A

Dopamine infusion 2-10mcg/kg/min or epi (same dosing)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

1st line treatment for nonstable tachycardia (BPM >150)

A

Immediate syncronized cardioversion narrow regular 50-100J or narrow irregular 120-200J

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

1st line treatment for narrow QRS stable SINUS tachycardia (BPM>150)

A

No medication indicated, just monitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

1st line treatment for narrow QRS stable nonsinus tachycardia (BPM>150)

A

Adenosine 6mg IV push by 20mL saline flush, 2nd dose 12mg IV (warn the patient they will experience transient chest discomfort, dyspnea, flushing, short lived tho)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

2nd line treatment for narrow QRS stable nonsinus tachycardia (BPM>150) or control of heart rate in stable patients tachycardic patients (2)

A
  • Rate control with IV nondihydropyradine ca2+ channel blocker such as diltiazem or verapamil
  • B blocker (metoprolol, atenolol, labetalol)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

1st line treatment for wide QRS stable nonsinus tachycardia (BPM>150)

A

Amiodarone (150mg/10min)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Morphine sulfate function

A

Opioid analgesic that also dilates blood vessels, IV morphine controls pain of MI and improves hemodynamics by promoting vasodilation, and reduces anxiety, useful in ACS but need to be cautious about respiratory depression, can reverse with naloxone (2-4mg IV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lidocaine function

A

Suppress ventricular fibrillation by raising threshold of fibrillation via same ca2+ channel activity that inhibits pain, can be used as alternative to amiodarone in cardiac arrest (Vfib or pulseless vtach)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

B blocker use in ACLS

A

Used to suppress supraventricular tachycardia (atrial fib and flutter) and reduce myocardial ischemia in MI,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Atropine adverse effects (4)

A
  • blurred vision
  • dilated pupils
  • dry mouth/nose
  • difficulty urinating
17
Q

Concurrent administration of ca2+ channels with IV B blockers can cause severe….

A

…hypotension

18
Q

These drugs antagonize effects of adenosine (2) and this drug potentiate it

A
  • caffeine and theophylline

- dipyridamole

19
Q

Sotalol function

A

B Blocker that has antiarrhythmic properties but also proarrhythmic properties that are very pronounced and is thus indicated in treatment of ventricular and supraventricualr arrhythmias without structural heart disease